News Column

Recent Findings from Osaka University Has Provided New Information about Immunotherapy

May 26, 2014



By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Research findings on Biotechnology are discussed in a new report. According to news reporting originating from Osaka, Japan, by NewsRx correspondents, research stated, "FOXP3(+)CD25(+)CD4(+) regulatory T (Treg) cells, crucial for the maintenance of immunological self-tolerance, are abundant in tumors. Most of them are chemo-attracted to tumor tissues, expanding locally and differentiating into a Treg-cell subpopulation that strongly suppresses the activation and expansion of tumor-antigen-specific effector T cells."

Our news editors obtained a quote from the research from Osaka University, "Several cancer immunotherapies targeting FOXP3(+)CD4(+) Treg cells, including depletion of Treg cells, are currently being tested in the clinic. In addition, clinical benefit of immune-checkpoint blockade, such as anti-CTLA-4 monoclonal antibody therapy, could be attributed at least in part to depletion of FOXP3(+)CD4(+) Treg cells from tumor tissues."

According to the news editors, the research concluded: "Thus, optimal strategies need to be established for reducing Treg cells or attenuating their suppressive activity in tumor tissues, together with activating and expanding tumor-specific effector T cells."

For more information on this research see: Regulatory T cells in cancer immunotherapy. Current Opinion in Immunology, 2014;27():1-7. Current Opinion in Immunology can be contacted at: Current Biology Ltd, 84 Theobalds Rd, London WC1X 8RR, England. (Elsevier - www.elsevier.com; Current Opinion in Immunology - www.elsevier.com/wps/product/cws_home/601305)

The news editors report that additional information may be obtained by contacting H. Nishikawa, Osaka University, WPI Immunol Frontier Res Center, Osaka 5650871, Japan (see also Biotechnology).

Keywords for this news article include: Asia, Biotechnology, Osaka, Japan, Cancer, Oncology, Immunology, CD Antigens, CD4 Antigens, HIV Receptors, Immunotherapy, Differentiation, Immunomodulation, Membrane Proteins, Biological Factors, T-Lymphocyte Antigens, Interleukin-16 Receptors

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Vaccine Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters